Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).

Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, Virgolini I

Nuclear medicine and biology1 May 1996Cited by 8 (Europe PMC)

PMID8832707DOI10.1016/0969-8051(96)00031-5PepBankPUB-08832707

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialOther
In 11 patients with primary or suspected recurrent medullary thyroid carcinoma, 123I-VIP receptor scanning did not show any primary, recurrent or metastatic tumor lesion.
In plain wordsIn 11 patients with medullary thyroid cancer, a scan with radioactive VIP did not show any tumor.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeTumor localization by 123I-VIP receptor scan
Study
n = 11
Outcome group
Diagnostic imaging · Cancer
Studied dose
150 MBq/1 microgramAs given in this study (human).
Source sentences
Summary
In none of the 11 patients did 123I-VIP-receptor scanning indicate primary, recurrent, or metastatic tumor lesions.
1 context sentence(design, population, supporting numbers)
Summary · context
In an approach to localize MTC lesions we performed comparative in vivo studies in 12 patients with primary MTC and in 4 patients with suspected recurrent MTC using 123I-VIP (150 MBq/1 microgram) and 111In-DTPA-D-Phe-1-octreotide (111In-OCT; 150 MBq/1 microgram).
Report a problemFND-0883270701
02LabEx vivo tissueActivity measurement
Low-affinity 123I-VIP receptors were present in 6 of 6 medullary thyroid carcinoma tissue samples.
In plain wordsIn lab tests, all 6 medullary thyroid cancer tissue samples had low-affinity binding sites for VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableLow-affinity VIP receptors in MTC tissue
Study
n = 6
MTC tissue samples
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
In vitro binding studies showed an absence of high-affinity VIP receptors in MTC tissue, whereas high-affinity 111In-OCT receptors were present in 4 of 6, and low-affinity 123I-VIP as well as 111In-OCT receptors were present in 6 of 6 MTC tissue samples.
Report a problemFND-0883270703
03LabEx vivo tissueActivity measurement
In-vitro binding studies found no high-affinity VIP receptors in medullary thyroid carcinoma tissue.
In plain wordsIn lab tests, medullary thyroid cancer tissue showed no high-affinity binding sites for VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHigh-affinity VIP receptors in MTC tissue
Study
n: not reported in source
MTC tissue samples
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
In vitro binding studies showed an absence of high-affinity VIP receptors in MTC tissue, whereas high-affinity 111In-OCT receptors were present in 4 of 6, and low-affinity 123I-VIP as well as 111In-OCT receptors were present in 6 of 6 MTC tissue samples.
Report a problemFND-0883270702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.